logo

For the Inventor, By the Inventor

Suffern, NY, United States of America

Dilip B Wadgaonkar

USPTO Granted Patents = 9 

 

Average Co-Inventor Count = 4.0

ph-index = 8

Forward Citations = 766(Granted Patents)


Company Filing History:

goldMedal9 out of 30 
 
Acura Pharmaceuticals, Inc.
 patents

Years Active: 2007-2016

Loading Chart...
Loading Chart...
9 patents (USPTO):Explore Patents
1. 9492443 - Abuse deterrent compositions and methods of making same (2016-11-15),
2. 8822489 - Abuse deterrent compositions and methods of making same (2014-09-02),
3. 8637540 - Compositions for deterring abuse of opioid containing dosage forms (2014-01-28),
4. 8409616 - Extended release opioid abuse deterrent compositions and methods of making same (2013-04-02),
5. 8101630 - Extended release opioid abuse deterrent compositions and methods of making same (2012-01-24),
6. 7981439 - Methods and compositions for deterring abuse of drugs susceptible to abuse and dosage forms thereof (2011-07-19),
7. 7510726 - Methods and compositions for deterring abuse of opioid containing dosage forms (2009-03-31),
8. 7476402 - Methods and compositions for deterring abuse of opioid containing dosage forms (2009-01-13),
9. 7201920 - Methods and compositions for deterring abuse of opioid containing dosage forms (2007-04-10),

Title: Inventor Spotlight: Dilip B. Wadgaonkar

Introduction

Dilip B. Wadgaonkar, based in Suffern, NY, is a notable inventor with an impressive portfolio of nine patents to his name. His work primarily focuses on pharmaceutical innovations that contribute to safer therapeutic applications.

Latest Patents

Among his most recent inventions are the "Abuse Deterrent Compositions and Methods of Making Same." This invention presents a therapeutic pharmaceutical composition consisting of a mixture that includes an opioid, polyethylene oxide in quantities ranging from 3% to 40% weight of the composition, a disintegrant, and a surfactant. The design ensures that the pharmaceutical composition exhibits an immediate release profile, which can enhance patient safety and medication adherence. Additionally, he has developed an abuse deterrent dosage form of opioid analgesics. This form aptly combines an analgesically effective amount of opioid analgesic with a polymer to create a protective matrix, designed to deter misuse.

Career Highlights

Dilip B. Wadgaonkar has built a substantial career at Acura Pharmaceuticals, Inc., where he contributes his expertise in developing innovative pharmaceutical solutions. His work has significantly impacted the medical field, particularly in the area of pain management and addiction prevention.

Collaborations

Throughout his career, Wadgaonkar has collaborated with esteemed colleagues, including Vijai Kumar and David Dixon. Together, they have advanced the dialogue and developments in pharmaceutical technology, showcasing the power of teamwork in fostering innovation.

Conclusion

Dilip B. Wadgaonkar's contributions highlight the importance of innovation in the pharmaceutical industry. His dedication to creating safer and more effective therapeutic compositions underscores the ongoing need for research and development in combating misuse of opioids. As he continues to push the boundaries of pharmaceutical inventions, Wadgaonkar remains a key figure to watch in the field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…